Alethio Therapeutics Launches with New CEO and Chair to Advance Two Targeted Medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)




Alethio Therapeutics Launches with New CEO and Chair to Advance Two Targeted Medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)

• Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells
• Advancing AT-01, a first-in-class ADC programme, with strong preclinical validation towards IND/CTA-enabling studies, expected to begin in the first half of 2026
• AT-02 further expands ADC portfolio by targeting mutant CALR, a key MPN driver mutation
• Leadership and Board strengthened with appointments of Dr Rohit Batta as CEO and Mike Grey as Chair

Oxford, UK – 30 October 2025 – Alethio Therapeutics, a biotech company advancing therapies designed to help people with Myeloproliferative Neoplasms (MPNs) live longer, healthier, and more fulfilling lives, today emerges from stealth with two antibody-drug conjugate (ADC) programmes and the appointments of Dr Rohit Batta as Chief Executive Officer and Mike Grey as Chair of the Board. Backed by deep scientific and clinical expertise, Alethio Therapeutics is focused on translating its discovery insights into a pipeline of precision, disease-modifying therapies.

MPNs form a group of chronic, incurable and ultimately fatal blood cancers. Approximately 300,000 people in the US live with MPNs and existing approved therapies, such as JAK inhibitors, are largely symptomatic, meaning they do not eliminate the malignant cells or alter disease progression. Patients face premature death and severe quality-of-life impairment, and disease-modifying treatments are desperately needed.

Leveraging deep expertise in MPNs to drive a pipeline of disease-modifying therapies

Alethio Therapeutics brings decades of clinical expertise in MPNs and MPN biology from its founders, Professors Adam Mead and Beth Psaila from the University of Oxford. Alongside this, its powerful ARTEMIS discovery engine enables the Company to identify and validate novel targets, using access to one of the world’s largest MPN patient cell repositories, and to develop first-in-class medicines against these targets. ARTEMIS also enables Alethio Therapeutics to de-risk candidates before clinical trials using advanced human bone marrow organoid models that replicate patient biology.

Advancing AT-01, a first-in-class ADC programme targeting disease-driving cells in MPN towards clinical proof of concept

Alethio Therapeutic’s lead programme, AT-01, discovered and validated using ARTEMIS, is a first-in-class ADC designed and optimised to penetrate fibrotic bone marrow and target and eliminate disease-driving cells in MPN. AT-01 is based on a novel target, which is uniquely upregulated on disease-driving stem cells and fibrosis-driving megakaryocytes.

AT-01 has demonstrated compelling disease-modifying potential in preclinical studies, with a favourable therapeutic index for MPNs, including:

• Potent selectivity and cytotoxicity in eliminating mutant stem cells while sparing healthy peripheral blood mononuclear cells (PBMCs) and
• Reducing spleen size and fibrosis-driving cells, both predictive of improved clinical benefit

• Validation across multiple in vivo disease models, including founder-developed systems built over decades of research, as well as models using patient-derived cells in human bone marrow organoids that mimic the immunologically hostile myelofibrotic tumour microenvironment.

Alethio Therapeutics’ goal is to shift MPN treatment from symptom control towards disease modification to meet a critical patient need. The Company is currently preparing AT-01 for IND/CTA-enabling studies, expected to begin in the first half of 2026.

The Company is also advancing a second ADC programme AT-02, which targets mutant CALR and is undergoing preclinical evaluation. Mutant CALR is a major driver of MPN, found in ~30% of patients. It’s a standout target that is mutant-specific, surface-exposed, and ideal for an ADC therapeutic.

Strengthened leadership and board driving Alethio Therapeutics’ focused strategy

To drive Alethio Therapeutics’ discovery and development strategy in MPN, the Company today announces a strengthening and expansion of the leadership team and board with the appointments of Dr Rohit Batta as Chief Executive Officer and Mike Grey as Chair of the Board, succeeding Mark Throsby who remains on the board as a Non-Executive Director.

Rohit Batta joins Alethio Therapeutics from Ferring Ventures, where he served as Managing Director and Head of the group company. Previously, he was Chief Medical Officer at Vicore Pharma and also held senior leadership roles at GSK, where he led the clinical strategy for haemoglobinopathy gene therapies and played a pivotal role in launching the world’s first gene therapy for a paediatric rare disease – an achievement that earned his team a prestigious Prix Galien award. Rohit brings 20 years of industry experience in translating breakthrough science into therapies and strategic partnerships. He began his career as a physician in the UK’s National Health Service, and has worked across multiple clinical specialties including oncology.

Mike Grey is a seasoned leader with over 45 years of operational and board experience from biopharma, global pharma and venture capital. He has founded and grown several biotechnology companies and is currently Chair/Executive Chair of Mirum Pharmaceuticals, Sorriso Pharmaceuticals, Spruce Biosciences, Plexium and Theolytics. He also serves as Venture Partner with Pappas Capital.

He joins Mark Throsby, Suman Shirodkar, and Beth Psaila on the Alethio Therapeutics Board. Mark Throsby is a biopharma executive and antibody engineering expert with leadership roles at Crucell, Merus, and Gadeta, and over 40 publications and multiple patents. Suman Shirodkar is a biotech leader with 25 years of experience, who led the European launch of Jakafi for MPN – contributing to its over $3B annual revenue – and most recently served as CEO of Larkspur Biosciences and Cambridge Epigenetix, and is Chair of NanoPhoria.

Founding investor Oxford Science Enterprises is represented on the Board by Sally Dewhurst and Sanne De Jongh bringing significant experience in venture investing and company building based on cutting-edge science.
Alethio Therapeutics is headquartered at Abingdon Science Park, near Oxford, with state-of-the-art labs supporting its growth and the delivery of key development milestones with AT-01 and across its pipeline. Formerly known as Alethiomics, the new company name marks the next chapter in Alethio Therapeutics evolution – from early scientific exploration to the development of disease-modifying precision medicines for MPNs.

“With no curative options, MPNs expose patients to ongoing risk of disease evolution and poor outcomes,” said Rohit Batta, CEO. “Alethio Therapeutics is entering a new chapter with the ambition and team to deliver the first disease-modifying ADC therapies for MPNs. While current treatments are largely symptomatic, our unique expertise and approach enable us to directly target the drivers of disease progression, with the aim of shifting the treatment paradigm for MPNs and transforming outcomes for patients. It’s an exciting time to be joining Alethio Therapeutics, and I look forward to working with our founders, Beth Psaila and Adam Mead – leading MPN clinicians – our strategic board, and a talented team with deep expertise in cancer cell biology, organoid development, and bioinformatics, as we advance AT-01 and build our pipeline.”

“Alethio Therapeutics is advancing its lead programme to the clinic, benefitting from the capabilities it has assembled for the creation of disease-modifying medicines for chronic blood cancers where existing treatments are inadequate,” added Mike Grey, Chair of the Board. “The Company combines a wealth of expertise around MPN disease biology and treatment, target discovery and ADC development, which has the potential to unlock untapped opportunities in MPNs and fuel a pipeline of disease-modifying precision therapies. I’d like to thank Mark Throsby for his leadership as Chair and look forward to working alongside him and the broader team as we execute our new, focused strategy.”

ENDS

Contacts

Rohit Batta, CEO Alethio Therapeutics
rohit.batta@alethiomics.com

Mark Swallow, Sandi Greenwood, MEDiSTRAVA
AlethioTx@Medistrava.com

Notes to Editors

About Alethio Therapeutics
Alethio Therapeutics is pioneering the development of disease-modifying therapies for patients with chronic blood cancers, with the aim of helping them live fully, freely, and well. Formerly known as Alethiomics, Alethio Therapeutics is specifically focused on myeloproliferative neoplasms (MPNs), a group of chronic, incurable, and ultimately fatal blood cancers, where currently approved treatments – such as JAK inhibitors – are not selectively targeting disease-driving cells and primarily offer symptomatic relief. The Company’s lead programme, AT-01, is a first-in-class antibody drug conjugate (ADC) based on a novel target identified on MPN mutant stem cells that drive MPN disease progression. Alethio Therapeutics has generated compelling preclinical data for AT-01 demonstrating elimination of targeted cells, paving the way for IND-enabling studies in 2026. The Company is leveraging its expertise in MPN biology, bone marrow organoids, and ADC technology to advance AT-02, its second ADC candidate targeting mutant CALR – a key driver mutation in MPNs – currently in preclinical development. Alethio Therapeutics’ proprietary discovery engine, ARTEMIS, integrates access to leading MPN biobanks, single-cell sequencing, organoids, and bioinformatics to de-risk first-in-human trials and identify new mutant drivers, expanding therapeutic reach and market potential. Alethio Therapeutics is led by a highly experienced team and board, with Oxford Science Enterprises as its anchor investor.
www.alethiotherapeutics.com

About Oxford Science Enterprises
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company that finds, funds and builds transformational science and technology companies emerging from Oxford’s world-leading research. Our portfolio of companies is focused across three high-impact sectors – Deep Tech, Life Sciences, and HealthTech – with the ambition of tackling some of the world’s greatest challenges. To date, OSE has collaborated with over 300 international investors, collectively investing over £3 billion in more than 100 groundbreaking companies.
https://www.oxfordscienceenterprises.com/

Attachments

• Rohit Batta
• Mike Grey

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development




Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting discounts and commissions and offering expenses. In connection with the Underwritten Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 703,703 ordinary shares at a price of $20.25 per share.

Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes.

The financing consists of an underwritten offering (the “Underwritten Offering”) of 4,691,358 ordinary shares and a registered direct offering to an investor of 740,740 ordinary shares (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”). The Offerings are expected to close on or about November 3, 2025, subject to satisfaction of customary closing conditions. Of the shares being offered, including shares underlying the underwriters’ option, 2,635,801 are new shares that will be issued out of the Company’s existing capital band (Kapitalband) before closing and 3,500,000 are shares previously held in treasury by the Company. The issuance of the new shares will bring the total number of registered shares authorized by the Company as per its Articles of Association up to 57,169,475.

J.P. Morgan, Leerink Partners and Pareto Securities are acting as joint bookrunning managers for the Underwritten Offering. Van Lanschot Kempen is acting as manager for the Underwritten Offering. Arctica Finance is acting as financial advisor for the Underwritten Offering.

The Offerings are being made pursuant to a registration statement on Form F-3, including a base prospectus, that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) on April 1, 2024 and declared effective on April 3, 2024. The shares referred to in this press release are being offered in the United States only by means of a prospectus supplement. Final prospectus supplements and accompanying prospectuses relating to the Offerings will be filed with the SEC and will be available at no cost on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement for the Underwritten Offering and the accompanying prospectus may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@jpmchase.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105 or by email at syndicate@leerink.com; or Pareto Securities AB, Berzelii Park 9, P.O. Box 7415, 103 91 Stockholm, Sweden, or email: info@paretosec.com.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

Important Information

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

With respect to the member States of the European Economic Area (a “Relevant Member State”), no action has been undertaken or will be undertaken to make an offer to the public of the shares referred to herein requiring a publication of a prospectus in any Relevant Member State. As a result, the shares may not and will not be offered in any Relevant Member State except in accordance with the exemptions set forth in Article 1(4) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 on the prospectus to be published when shares are offered to the public admitted to trading on a regulated market, as amended (the “Prospectus Regulation”) or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Regulation and/or to applicable regulations of that Relevant Member State.

In addition, in the United Kingdom, this announcement is directed at and for distribution only to Qualified Investors who are (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and (iii) other persons to whom this announcement may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The shares referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such shares will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this communication or any of its contents.

No announcement or information regarding these Offerings may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. Other than the registration statement filed with the SEC, no steps have been taken, or will be taken, for the Offerings of shares in any jurisdiction where such steps would be required. The issue or sale of shares, and the subscription for or purchase of shares, are subject to special legal or statutory restrictions in certain jurisdictions. Oculis is not liable if these restrictions are not complied with by any person.

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com 

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the expected closing of the Offerings and the expected use of proceeds from the Offerings are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F, the prospectus supplements related to these Offerings and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development




Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting discounts and commissions and offering expenses. In connection with the Underwritten Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 703,703 ordinary shares at a price of $20.25 per share.

Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes.

The financing consists of an underwritten offering (the “Underwritten Offering”) of 4,691,358 ordinary shares and a registered direct offering to an investor of 740,740 ordinary shares (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”). The Offerings are expected to close on or about November 3, 2025, subject to satisfaction of customary closing conditions. Of the shares being offered, including shares underlying the underwriters’ option, 2,635,801 are new shares that will be issued out of the Company’s existing capital band (Kapitalband) before closing and 3,500,000 are shares previously held in treasury by the Company. The issuance of the new shares will bring the total number of registered shares authorized by the Company as per its Articles of Association up to 57,169,475.

J.P. Morgan, Leerink Partners and Pareto Securities are acting as joint bookrunning managers for the Underwritten Offering. Van Lanschot Kempen is acting as manager for the Underwritten Offering. Arctica Finance is acting as financial advisor for the Underwritten Offering.

The Offerings are being made pursuant to a registration statement on Form F-3, including a base prospectus, that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) on April 1, 2024 and declared effective on April 3, 2024. The shares referred to in this press release are being offered in the United States only by means of a prospectus supplement. Final prospectus supplements and accompanying prospectuses relating to the Offerings will be filed with the SEC and will be available at no cost on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement for the Underwritten Offering and the accompanying prospectus may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@jpmchase.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105 or by email at syndicate@leerink.com; or Pareto Securities AB, Berzelii Park 9, P.O. Box 7415, 103 91 Stockholm, Sweden, or email: info@paretosec.com.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

Important Information

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

With respect to the member States of the European Economic Area (a “Relevant Member State”), no action has been undertaken or will be undertaken to make an offer to the public of the shares referred to herein requiring a publication of a prospectus in any Relevant Member State. As a result, the shares may not and will not be offered in any Relevant Member State except in accordance with the exemptions set forth in Article 1(4) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 on the prospectus to be published when shares are offered to the public admitted to trading on a regulated market, as amended (the “Prospectus Regulation”) or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Regulation and/or to applicable regulations of that Relevant Member State.

In addition, in the United Kingdom, this announcement is directed at and for distribution only to Qualified Investors who are (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and (iii) other persons to whom this announcement may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The shares referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such shares will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this communication or any of its contents.

No announcement or information regarding these Offerings may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. Other than the registration statement filed with the SEC, no steps have been taken, or will be taken, for the Offerings of shares in any jurisdiction where such steps would be required. The issue or sale of shares, and the subscription for or purchase of shares, are subject to special legal or statutory restrictions in certain jurisdictions. Oculis is not liable if these restrictions are not complied with by any person.

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com 

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the expected closing of the Offerings and the expected use of proceeds from the Offerings are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F, the prospectus supplements related to these Offerings and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London




Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London

Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November 17-20, 2025.

Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Wednesday, November 19 at 10:00 GMT/11:00 CET. A live webcast and replay of the presentation can be found in the “Upcoming Events” and “News” sections of Pharming’s website.

For more information about the conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Investor Relations at investor@pharming.com or your Jefferies representative.

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

Media Relations
Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: media.relations@pharming.com

U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

• Pharming Fireside Chat at Jefferies Global Healthcare Conference in London_EN_30OCT25

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting




DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Châtillon, France, October 30, 2025

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 – 10, in Orlando, Florida.

DBV will host a Product Theater titled “Harnessing Immune Plasticity to Alter the Path of Food Allergy”. A panel of renowned allergists, Drs. Gideon Lack, Hugh Sampson, George du Toit, Kirsten Perrett and Matthew Greenhawt, will discuss immunological and clinical evidence in support of the benefits of earlier intervention in food allergy management. During the presentation, Dr. Perrett will present details of a planned Phase 2 clinical study in which DBV will assess the efficacy and safety of the VIASKIN^® Peanut patch in achieving ad lib consumption of dietary peanut in peanut-allergic infants 6 through 12 months of age following a minimum of 3 years of treatment.

Product Theater Details:

• Date: Saturday, November 8, 2025
• Time: 11:35 a.m. to 1:00 p.m. ET
• Location: West Hall E

“We’re beginning to see a shift towards a more proactive approach to food allergy management, both when it comes to early introduction of potential allergens and the use of immunomodulatory interventions,” stated Dr. Gideon Lack, Professor of Pediatric Allergy, London Allergy Care and Knowledge and co-principal investigator of the Phase 2 early intervention clinical study. “With this upcoming study, we now have an opportunity to investigate if earlier intervention with the VIASKIN^® Peanut patch, a potentially disease-modifying immunotherapy, can help achieve ad lib peanut consumption in children aged 6 to 12 months.”

This year’s meeting will also feature a presentation by Dr. Matthew Greenhawt on the end-of-study results from the open-label extension to the EPITOPE study (EPOPEX) as part of the “Distinguished Industry and Late-breaking Oral Abstract” session.

“With our product theater announcing a first-of-its-kind phase 2 study to assess if the VIASKIN® Peanut patch can achieve ad lib consumption, and compelling end-of-study results from the three-year EPOPEX study, our well-rounded presence at this year’s meeting is representative of our work and commitment to the younger patient population within the food allergy community,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “In addition to DBV’s highlighted clinical efforts in this younger patient population, we have line-of-sight to a potential BLA filing for VIASKIN® Peanut patch for toddlers ages 1 – 3 years in the second half of next year under an Accelerated Approval Pathway as previously agreed upon with the FDA.”

Oral Scientific Presentation Details:

• “Long-Term Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: EPOPEX End-of-Study Results” will be presented by Dr. Matthew Greenhawt
• Session: Distinguished Industry & Late-breaking Oral Abstracts – Session 2
• Date: Saturday, November 8, 2025
• Session time: 4:30 to 6:00 p.m. ET
• Presentation time: 4:43 p.m. ET
• Location: Room W231

The Company will exhibit at booth #711 and is sponsoring the 34th Annual FIT Bowl™, a game show-type competition that tests allergy, asthma, and immunology knowledge of participating teams from training programs around the country. The competition is set to be held on Saturday, November 8th, from 5:45 p.m. to 7:45 p.m. ET.

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN^® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN^® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN^® Peanut patch and EPIT, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations with respect to the submission of BLAs to FDA, anticipated support for the BLA submission, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

Latest Data of InnoCare’s Zurletrectinib Orally Presented at SIOP 2025




Latest Data of InnoCare’s Zurletrectinib Orally Presented at SIOP 2025

BEIJING, Oct. 29, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data of its next generation pan-TRK inhibitor zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors. The data from the phase I/II clinical trial has been released at the Congress of International Society of Paediatric Oncology (SIOP) 2025 as an oral presentation.

Oral Presentation

Professor Yizhuo Zhang, from the Department of Pediatric Oncology at the Sun Yat-sen University Cancer Center, is the leading PI of the study. Professor Juan Wang, representing the multicenter investigators team, delivered an oral presentation at the Congress entitled “Safety, pharmacokinetics, and efficacy of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients with advanced solid tumor: a Phase I/II trial”.

In this study, zurletrectinib demonstrated favorable/well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors, The results/data highlight zurletrectinib’s strong potential as a next-generation therapy for NTRK/ROS1-driven malignancies, with the ability to overcoming resistance to first-generation TRK inhibitors.

The predominant tumor types included NTRK-rearranged spindle cell tumors and primary central nervous system tumors. The Recommended Phase 2 Dose (RP2D) was determined to be 7.2 mg/m² for pediatric patients and 8 mg for adolescents. Pharmacokinetic (PK) profiles at the RP2D showed comparable exposer levels between pediatric/adolescent and adult patients.

As of July 31, 2025, the objective response rate (ORR) was 90% in NTRK fusion patients, as assessed by the Independent Review Committee (IRC). Among the patients who completed full efficacy evaluations, all of those who were resistant to first-generation TRK inhibitors achieved partial responses.

No dose-limiting toxicities were observed. Treatment related adverse events (TRAEs) were predominantly grade 1~2, indicating a favorable safety profile.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

Contact

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day




Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-siRNA)” – “Next steps.”

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well tolerated to date

Activin E reduction in lowest dose cohort of INLIGHT was sustained through 6 months, supporting once or twice a year dosing

Multiple clinical data updates from INLIGHT, including body composition and body weight, are anticipated starting in 4Q 2025

Additional updates included announcement of WVE-008, PNPLA3 RNA editing candidate for liver disease, with CTA submission anticipated in 2026

Preclinical data supports Wave’s emerging pipeline of hepatic and extra-hepatic RNA editing and siRNA programs; emerging modality adds capability to simultaneously edit and silence two unique targets with a single oligonucleotide construct

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced Activin E target engagement data from its INLIGHT clinical trial of WVE-007, a GalNAc-siRNA, for the treatment of obesity during the company’s annual analyst and investor Research Day.

“We are incredibly excited to be observing potent, durable, and dose-dependent Activin E reductions with just single doses of WVE-007 in the first three cohorts of our INLIGHT clinical trial for obesity. This indicates our preclinical data are translating and affirms we have a potential best-in-class RNAi modality enabled by our proprietary chemistry, including PN,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “We also continue to lead the field in RNA editing. With the successful clinical translation of WVE-006 for AATD, we are further expanding our editing pipeline and have now selected WVE-008 as our PNPLA3 RNA editing clinical candidate for liver disease. WVE-008 is on track to enter clinical development next year with the filing of a CTA. In addition to that, we are pioneering a new modality by uniting editing and silencing in a single oligonucleotide construct. With multiple planned clinical updates across our RNA editing and RNAi programs, Wave is in a unique position to unlock tremendous value from our robust RNA medicines pipeline.”

INLIGHT clinical study and target engagement update:

WVE-007 (GalNAc-siRNA): INHBE silencing approach designed to reduce fat while preserving muscle mass

• Wave’s INHBE program has a strong foundation in human genetics. People living with naturally low levels of INHBE have lower levels of unhealthy visceral fat, lower fasting glucose and triglycerides, and a lower risk of type 2 diabetes and cardiovascular disease. Silencing INHBE mRNA aims to reduce Activin E levels, thereby inducing fat loss without impacting muscle mass.
• In Wave’s preclinical studies of mice with diet-induced obesity (DIO), single doses of GalNAc INHBE-siRNA led to potent and durable Activin E reductions of greater than 70%, and weight loss driven by reduction in visceral fat, without affecting muscle mass. Preclinical studies also support the use of INHBE GalNAc-siRNA as an add-on to GLP-1s or to curtail weight regain following cessation of GLP-1s. These reduced Activin E levels led to adipocyte shrinkage, fewer pro-inflammatory macrophages, less fibrosis, and improved insulin sensitivity in visceral adipose tissue, linking increased lipolysis to lower cardiometabolic risk.
• Today, Wave announced highly significant, dose-dependent Activin E reductions were observed in the first three cohorts of its ongoing INLIGHT clinical trial evaluating WVE-007 (3:1 active: placebo). The trial is designed to address safety and tolerability as well as target engagement (Activin E reduction). One-month follow-up was available from Cohort 2 (240 mg) and Cohort 3 (400 mg), and six-month follow-up from Cohort 1.
• At day 29 (one month post single dose), mean Activin E reductions from baseline were all highly significant (p<0.0001 for all doses):
  • Cohort 3 (400 mg): 85% reduction
  • Cohort 2 (240 mg): 75% reduction
  • Cohort 1 (75 mg): 56% reduction
• The one-month reductions of Activin E observed in the 240 mg and 400 mg cohorts exceed levels that led to fat loss in preclinical models.
• In Cohort 1 (75 mg), Activin E reductions were durable throughout the 6-month follow-up, supporting WVE-007’s potential for once or twice yearly doing.
• WVE-007 is safe and well tolerated to date. An independent data monitoring committee supported dose expansion of the 600 mg cohort and dose escalation beyond that.
• WVE-007 aims to achieve fat loss on par with semaglutide by six months of follow up post-single WVE-007 dose.
• Next steps: Wave expects to deliver multiple clinical data updates from INLIGHT, including body composition and body weight:
  • 4Q 2025: anticipated three-month follow-up data from the expanded Cohort 2 (240 mg), as well as data from Cohort 1 (75 mg).
  • 1Q 2026: anticipated six-month follow-up data from Cohort 2 and three-month follow-up data from Cohort 3.
  • 2Q 2026: anticipated six-month follow-up data from Cohort 3 and three-month follow-up data from Cohort 4.

Additional details can be found in the company’s Research Day presentation.

Additional updates from today’s presentation:

WVE-006 (RNA Editing): potential first- and best-in-class therapy for AATD that addresses both lung and liver manifestations of the disease

• The ongoing Phase 1b/2a RestorAATion-2 study is evaluating WVE-006, a GalNAc-conjugated RNA editing oligonucleotide, as a treatment for alpha-1 antitrypsin deficiency (AATD). The multidose portion of Cohort 2 is currently ongoing with monthly doses of 400 mg. Today, Wave announced Cohort 3 is now underway at doses of 600 mg of WVE-006.
• In September 2025, Wave announced WVE-006 has already achieved key treatment goals by restoring protein levels associated with lower risk of AATD liver and lung diseases. Total AAT levels reached 13 µM, wild-type M-AAT protein accounted for 64% of circulating total AAT after treatment, with a corresponding reduction in Z-AAT. Notably, WVE-006 restored the ability to dynamically produce therapeutically relevant levels of AAT protein during an acute phase response, with an individual reaching over 20 µM AAT protein.
• Next steps: 400 mg multidose cohort data expected in the first quarter of 2026; 600 mg single dosing is underway in the third and final cohort, with single and multi-dose data expected in 2026.

WVE-008 (RNA Editing): potential first-in-class, disease modifying therapy for PNPLA3-I148M liver disease

• Building on the successful clinical translation of Wave’s RNA editing capability, the company has selected WVE-008 as its clinical candidate for PNPLA3-I148M liver disease.
• There are an estimated 9 million homozygous PNPLA3-I148M individuals with liver disease in the U.S. and Europe. These homozygous carriers have a significantly higher risk of liver-related death compared to heterozygous carriers. Wave’s RNA editing approach aims to achieve at least 50% correction to restore the heterozygous phenotype with low risk of liver disease, similar to the approach with WVE-006.
• Next steps: Wave expects to file a Clinical Trial Application (CTA) for WVE-008 in 2026.

Wave’s platform innovations: extra-hepatic delivery and an emerging new modality

• Through chemistry optimization tailored to target and cell type, Wave is expanding its emerging pipeline of siRNAs (SpiNAs) and RNA editing oligonucleotides (AIMers) to both hepatic and extrahepatic tissues, including skeletal muscle, heart, adipose, and kidney.
• Emerging modality adds capability to simultaneously edit and silence two unique targets with a single oligonucleotide construct. Wave presented preclinical data demonstrating that a single GalNAc-oligonucleotide construct upregulated LDLR protein and silenced PCSK9 mRNA.

An archived webcast of the event can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, site activation, patient recruitment, patient enrollment, dosing, generation and reporting of data and completion of our clinical trials, including interactions with regulators and any potential registration based on these data, and the timing and announcement of such events; our understanding of the dose levels and dosing frequency of our therapeutic candidates; our understanding of the safety profile of our therapeutic candidates; our expectations for our clinical candidates and the anticipated therapeutic benefits thereof; the potential of WVE-007’s mechanism (INHBE) as a novel and unique obesity treatment to induce fat loss, preserve muscle, and drive weight loss; the anticipated therapeutic benefits of WVE-006 as a therapy for AATD and the potential to address both lung and liver manifestations of the disease; our understanding of the anticipated therapeutic benefits of WVE-008 as a therapy for PNPLA3-I148M liver disease; regulatory submissions and timing for regulatory feedback; the protocol, design and endpoints of our clinical trials; the future performance and results of our programs in clinical trials; our expectations with respect to how our preclinical and clinical data successes to date may predict success for our future therapeutic candidates, future clinical data readouts and further validate of our platform; the potential of our preclinical data to predict the behavior of our compounds in humans; our identification and expected timing of future product candidates and clinical-stage programs and their therapeutic potential; the anticipated benefits of our therapeutic candidates and pipeline compared to our competitors; patient population estimates related to our therapeutic candidates and the potential addressable market that our therapeutics may address; our ability to design compounds using various modalities and the anticipated benefits of that approach; the breadth and versatility of our PRISM drug discovery and development platform; the expected benefits of our stereopure oligonucleotides compared with stereorandom oligonucleotides; the potential benefits of our RNA editing capability, including our AIMers, compared to others; the potential benefits of our emerging pipeline of siRNAs (SpiNAs) compared to others; the benefits of RNA medicines generally; the potential for certain of our programs to be best-in-class or first-in-class; our ability to translate genetic insights into high impact medicines; the status and progress of our programs relative to potential competitors; the progress and potential benefits of our collaborations; our expectations on the company’s future growth; and the anticipated duration of our cash runway and our ability to fund future operations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

Specialist Direct’s ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes




Specialist Direct’s ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes

Strategic integration of advanced health engagement technology to enhance recovery journeys and promote healthier lifestyles

Zurich, Switzerland, Oct. 29, 2025 (GLOBE NEWSWIRE) — Specialist Direct, a digital health solutions subsidiary company of Swisstec, announced a global strategic partnership with dacadoo, a digital health engagement company. Mira, Specialist Direct’s case management platform, is focused on guiding patients through injury and illness recovery. dacadoo’s Digital Health Engagement Platform (DHEP) is focused on empowering lifestyle change and wellness management. By integrating these two distinct strengths, the partnership delivers a seamless continuum of care, with Mira managing recovery from injury and illness, and dacadoo driving lifestyle change, and wellness management.  

dacadoo–Specialist Direct global partnership on recovery and wellness

Recovery and Beyond: Transforming Recovery Through Holistic Health Engagement 

This partnership represents a significant advancement in case management technology, aligning with Specialist Direct’s mission to reshape healthcare and improve people’s wellbeing through early intervention and identification of lifestyle risk factors. By embedding dacadoo’s science-backed Health Score, powered by over 400 million person-years of clinical data, Mira will now provide to its users: 

• Comprehensive health scoring that tracks personal development across physical, mental, and lifestyle factors 

• AI-driven personalised recommendations to foster steady improvement and promote lasting lifestyle health 

• Evidence-based wellness strategies tailored to encourage healthier daily choices 

• Gamified wellness programs that inspire ongoing healthy habits and long-term lifestyle improvements 
• Personalised lifestyle challenges and tips that support long-term health and promote lasting wellbeing 

Impact on Case Management 

For Mira’s expanding user base across organisations, sports clubs, and healthcare providers, this partnership delivers immediate and measurable value: 

Enhanced Lifestyle Outcomes 

• Promote timely return-to-work / return-to-play timelines by fostering healthier routines and balanced habits 

• Support long-term wellbeing by promoting sustainable lifestyle improvements 
• Strengthen overall vitality through personalised, evidence-based lifestyle engagement 

Wellbeing and Resilience  

• Build healthier daily practices through improved lifestyle and wellness management 
• Foster early identification of lifestyle factors before they impact wellbeing in work or sport settings  

• Strengthened employee and player resilience through proactive wellness programs 

Seamless Integration 

• Unified platform experience within Mira’s existing case management ecosystem 

• Real-time health insights integrated with engagement and communication tools 

• 24/7 access to wellness guidance through Mira’s mobile platform 

Benefits for Corporate Organisations 

• Potentially reduce workers’ compensation costs by promoting everyday health 

• Strengthen organisational lifestyle management 

• Enhanced duty of care through comprehensive wellbeing support 

This collaboration places both companies at the forefront of digital health innovation in the occupational health and lifestyle engagement. dacadoo’s platform is already trusted by leading insurers, banks, retailers and healthcare providers worldwide, while Mira has demonstrated proven success within Australian Football the Victorian Amateur Football Association (VAFA) and is expanding across other sports and workplace health sectors internationally. 

“We’re excited to integrate dacadoo’s proven health engagement technology into our health ecosystem”, said Afifa Loutfie, Managing Director at Specialist Direct. “This partnership perfectly aligns with our commitment to empowering individuals to lead healthier lifestyles while helping organisations enhance their governance and foster resilience and wellbeing.”  

“Our partnership with Specialist Direct integrates dacadoo’s Health Score and engagement technology into Mira’s wellness pathways, delivering measurable benefits for health improvement and sustained wellbeing. Together, we’re setting a new standard for innovative, outcome-driven digital health support.“, said Peter Ohnemus, President & CEO at dacadoo. 

The dacadoo platform integration is scheduled to commence in the upcoming months as part of this global partnership, with an initial focus on Australia, Asia, the Middle East, and Europe, and will be available to Mira users starting 2026. 

About Specialist Direct 

Specialist Direct is an Australian digital health solution company committed to building an ecosystem that bridges healthcare gaps and breaks silos within the industry to achieve better outcomes. Through their flagship and proprietary Mira platform, Specialist Direct empowers individuals to take proactive steps in their recovery from injury or illness while enabling organisations to enhance their governance and risk management approach.  

About dacadoo

dacadoo is a Swiss-based technology company that develops technology solutions for digital health engagement and health risk quantification. Our Enterprise SaaS based digital health engagement platform (DHEP) is a mobile-first solution that leverages behavioral science, AI, and gamification to help end-users improve their health outcomes while helping clients to improve customer engagement and loyalty through personalization. This platform is available in over 18 languages and can be licensed as a white label offering or through APIs to develop/enhance custom solutions. Our award-winning Risk Engine, which calculates relative risk on mortality and morbidity in real-time, is also available for license through APIs. dacadoo’s global employees are committed to making the world a healthier place. We strongly value security and privacy, with an Information Security and Privacy Management System certified to ISO 27001 and ISO 27701 standards.

Press inquiries

dacadoo
https://www.dacadoo.com/
Masako Boskovski
marketing@dacadoo.com
Othmarstrasse 8. CH-8008 Zurich Switzerland

Specialist Direct’s ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes




Specialist Direct’s ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes

Strategic integration of advanced health engagement technology to enhance recovery journeys and promote healthier lifestyles

Zurich, Switzerland, Oct. 29, 2025 (GLOBE NEWSWIRE) — Specialist Direct, a digital health solutions subsidiary company of Swisstec, announced a global strategic partnership with dacadoo, a digital health engagement company. Mira, Specialist Direct’s case management platform, is focused on guiding patients through injury and illness recovery. dacadoo’s Digital Health Engagement Platform (DHEP) is focused on empowering lifestyle change and wellness management. By integrating these two distinct strengths, the partnership delivers a seamless continuum of care, with Mira managing recovery from injury and illness, and dacadoo driving lifestyle change, and wellness management.  

dacadoo–Specialist Direct global partnership on recovery and wellness

Recovery and Beyond: Transforming Recovery Through Holistic Health Engagement 

This partnership represents a significant advancement in case management technology, aligning with Specialist Direct’s mission to reshape healthcare and improve people’s wellbeing through early intervention and identification of lifestyle risk factors. By embedding dacadoo’s science-backed Health Score, powered by over 400 million person-years of clinical data, Mira will now provide to its users: 

• Comprehensive health scoring that tracks personal development across physical, mental, and lifestyle factors 

• AI-driven personalised recommendations to foster steady improvement and promote lasting lifestyle health 

• Evidence-based wellness strategies tailored to encourage healthier daily choices 

• Gamified wellness programs that inspire ongoing healthy habits and long-term lifestyle improvements 
• Personalised lifestyle challenges and tips that support long-term health and promote lasting wellbeing 

Impact on Case Management 

For Mira’s expanding user base across organisations, sports clubs, and healthcare providers, this partnership delivers immediate and measurable value: 

Enhanced Lifestyle Outcomes 

• Promote timely return-to-work / return-to-play timelines by fostering healthier routines and balanced habits 

• Support long-term wellbeing by promoting sustainable lifestyle improvements 
• Strengthen overall vitality through personalised, evidence-based lifestyle engagement 

Wellbeing and Resilience  

• Build healthier daily practices through improved lifestyle and wellness management 
• Foster early identification of lifestyle factors before they impact wellbeing in work or sport settings  

• Strengthened employee and player resilience through proactive wellness programs 

Seamless Integration 

• Unified platform experience within Mira’s existing case management ecosystem 

• Real-time health insights integrated with engagement and communication tools 

• 24/7 access to wellness guidance through Mira’s mobile platform 

Benefits for Corporate Organisations 

• Potentially reduce workers’ compensation costs by promoting everyday health 

• Strengthen organisational lifestyle management 

• Enhanced duty of care through comprehensive wellbeing support 

This collaboration places both companies at the forefront of digital health innovation in the occupational health and lifestyle engagement. dacadoo’s platform is already trusted by leading insurers, banks, retailers and healthcare providers worldwide, while Mira has demonstrated proven success within Australian Football the Victorian Amateur Football Association (VAFA) and is expanding across other sports and workplace health sectors internationally. 

“We’re excited to integrate dacadoo’s proven health engagement technology into our health ecosystem”, said Afifa Loutfie, Managing Director at Specialist Direct. “This partnership perfectly aligns with our commitment to empowering individuals to lead healthier lifestyles while helping organisations enhance their governance and foster resilience and wellbeing.”  

“Our partnership with Specialist Direct integrates dacadoo’s Health Score and engagement technology into Mira’s wellness pathways, delivering measurable benefits for health improvement and sustained wellbeing. Together, we’re setting a new standard for innovative, outcome-driven digital health support.“, said Peter Ohnemus, President & CEO at dacadoo. 

The dacadoo platform integration is scheduled to commence in the upcoming months as part of this global partnership, with an initial focus on Australia, Asia, the Middle East, and Europe, and will be available to Mira users starting 2026. 

About Specialist Direct 

Specialist Direct is an Australian digital health solution company committed to building an ecosystem that bridges healthcare gaps and breaks silos within the industry to achieve better outcomes. Through their flagship and proprietary Mira platform, Specialist Direct empowers individuals to take proactive steps in their recovery from injury or illness while enabling organisations to enhance their governance and risk management approach.  

About dacadoo

dacadoo is a Swiss-based technology company that develops technology solutions for digital health engagement and health risk quantification. Our Enterprise SaaS based digital health engagement platform (DHEP) is a mobile-first solution that leverages behavioral science, AI, and gamification to help end-users improve their health outcomes while helping clients to improve customer engagement and loyalty through personalization. This platform is available in over 18 languages and can be licensed as a white label offering or through APIs to develop/enhance custom solutions. Our award-winning Risk Engine, which calculates relative risk on mortality and morbidity in real-time, is also available for license through APIs. dacadoo’s global employees are committed to making the world a healthier place. We strongly value security and privacy, with an Information Security and Privacy Management System certified to ISO 27001 and ISO 27701 standards.

Press inquiries

dacadoo
https://www.dacadoo.com/
Masako Boskovski
marketing@dacadoo.com
Othmarstrasse 8. CH-8008 Zurich Switzerland

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025




Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management is scheduled to participate in the following investor conferences in November 2025.

• Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5
• Stifel 2025 Healthcare Conference: Presentation on November 13 at 2:40 pm EST

About Ascentage Pharma Group International

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key apoptotic pathway proteins, such as Bcl-2, MDM2, p53 as well as next-generation kinase inhibitors.

The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with chronic myelogenous leukemia (CML) in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), called POLARIS-1, and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) patients, called POLARIS-3.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia ( AML); and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS).

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777

Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282

Media Relations:
Jon Yu
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 677-1855